HUTCHMED Celebrates Positive Results in Lung Cancer Trial
HUTCHMED (China) Limited has recently unveiled compelling new findings from the SAVANNAH Phase II clinical trial. This groundbreaking study investigated the efficacy of TAGRISSO® (osimertinib) combined with ORPATHYS® (savolitinib) in patients suffering from non-small cell lung cancer (NSCLC) exhibiting high levels of MET overexpression or amplification. The results indicate a remarkable and clinically significant response rate in patients whose disease progressed under TAGRISSO treatment.
Understanding the Clinical Significance of MET Overexpression
EGFR mutation is a primary cause of NSCLC, which often leads to resistance mechanisms, particularly through MET pathways. The latest data from the SAVANNAH trial has shown that MET is a prevalent biomarker associated with resistance to EGFR-targeted therapies. Around 62% of participants screened exhibited MET overexpression or amplification, and nearly 34% qualified as having high MET levels upon disease progression.
Expert Insights on TAGRISSO and ORPATHYS Combination
Dr. Myung-Ju Ahn, a leading authority in hematology and oncology and principal investigator of the SAVANNAH trial, emphasized the transformative impact of osimertinib for patients with EGFR-mutated lung cancer. He pointed out that while osimertinib has significantly improved survival rates, many patients subsequently face resistance characterized by genetic alterations in MET. The addition of savolitinib offers an innovative approach that has already demonstrated promise in this challenging therapeutic landscape.
Industry Perspectives on the Treatment Strategy
Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca, also acknowledged the importance of this combination. She stated that the enhanced response rates reveal the value of targeted therapy in overcoming MET-driven resistance, reinforcing the strategy of continuing TAGRISSO while incorporating ORPATHYS for improved patient outcomes.
Safety Profile of the Combination Treatment
The safety and tolerability of the TAGRISSO and ORPATHYS regimen were on par with established findings for each drug. No novel safety concerns arose during the trial, providing reassurance for both physicians and patients considering this treatment pathway.
Looking Ahead: Future Clinical Trials and Developments
In tandem with this announcement, HUTCHMED is committed to elucidating the full potential of MET targeting within NSCLC. AstraZeneca is sponsoring the SAFFRON Phase III trial, focusing on comparing the combination of TAGRISSO and ORPATHYS against traditional platinum-based chemotherapy options for patients with advanced stages of NSCLC. This trial aims to prospectively assess patients using high MET level criteria established in the SAVANNAH trial.
About NSCLC and MET
Globally, lung cancer remains a leading cause of mortality in both sexes, responsible for approximately 20% of all cancer-related deaths. Non-small cell lung cancer constitutes the majority of such cases. With roughly 2.4 million annual diagnoses worldwide, a description of MET’s role in this cancer type becomes increasingly crucial, especially given its implications for treatment resistance and progression.
Overview of HUTCHMED’s Pipeline
With a robust pipeline of targeted therapies, HUTCHMED is defining its role in transforming cancer treatment paradigms. Their dedication spans the discovery and commercial development of innovative therapies aimed at improving survival rates for patients afflicted by various forms of cancer.
Frequently Asked Questions
What was the main finding of the SAVANNAH Phase II trial?
The main finding was that the combination of TAGRISSO and ORPATHYS demonstrated a high, clinically meaningful objective response rate in NSCLC patients with MET overexpression.
How common is MET overexpression in lung cancer patients?
In the SAVANNAH trial, approximately 62% of screened patients had tumors with MET overexpression or amplification.
What roles do TAGRISSO and ORPATHYS play in treating lung cancer?
TAGRISSO is an EGFR inhibitor, while ORPATHYS is a MET inhibitor. Their combination aims to overcome resistance mechanisms in NSCLC.
Are there additional trials involving TAGRISSO and ORPATHYS?
Yes, AstraZeneca is also sponsoring the SAFFRON Phase III trial to compare this combination to chemotherapy in advanced NSCLC.
How does HUTCHMED contribute to cancer treatment advancements?
HUTCHMED focuses on developing targeted therapies and immunotherapies, contributing to better treatment options and outcomes for cancer patients globally.
